Accéder au contenu
Merck

Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.

Archives of biochemistry and biophysics (2008-01-03)
Alicia Leikin-Frenkel, Paolo Parini, Fred M Konikoff, Lisbet Benthin, Diana Leikin-Gobbi, Ilana Goldiner, Curt Einarsson, Tuvia Gilat
RÉSUMÉ

Fatty acid bile acid conjugates (FABACs) prevent and dissolve cholesterol gallstones and prevent diet induced fatty liver, in mice. The present studies aimed to test their hypocholesterolemic effects in mice. Gallstone susceptible (C57L/J) mice, on high fat (HFD) or regular diet (RD), were treated with the conjugate of cholic acid with arachidic acid (FABAC; Aramchol). FABAC reduced the elevated plasma cholesterol levels induced by the HFD. In C57L/J mice, FABAC reduced plasma cholesterol by 50% (p<0.001). In mice fed HFD, hepatic cholesterol synthesis was reduced, whereas CYP7A1 activity and expression were increased by FABAC. The ratio of fecal bile acids/neutral sterols was increased, as was the total fecal sterol excretion. In conclusion, FABACs markedly reduce elevated plasma cholesterol in mice by reducing the hepatic synthesis of cholesterol, in conjunction with an increase of its catabolism and excretion from the body.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Arachidic acid, ≥99%
Sigma-Aldrich
Arachidic acid, synthetic, ≥99.0% (GC)